Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.50 |
| ▸ | FNTB | P49356 | 4/20 | 0.50 |
| ▸ | ACE | P12821 | 3/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14169908 | 0.84 | ACE (0.43) | FNTAFNTBACEMMEHRH4 | |
| SCHEMBL7937458 | 0.77 | HDAC1 (0.56) | FNTAFNTBACEKCNH2HPGD | |
| SCHEMBL7937461 | 0.77 | HDAC1 (0.56) | FNTAFNTBACEKCNH2HPGD | |
| SCHEMBL14169913 | 0.76 | ADRA2A (0.46) | KCNH2TSHR | |
| Hydrochloric Acid SCHEMBL7927540 | 0.75 | HDAC1 (0.55) | FNTAFNTBACEKCNH2HPGD | |
| SCHEMBL14169906 | 0.75 | RAB9A (0.45) | FNTAFNTBACEMMEKCNH2 | |
| SCHEMBL14170253 | 0.75 | CACNA1G (0.43) | KCNH2CACNA1GCACNA1HCACNA1I | |
| SCHEMBL14169937 | 0.75 | DRD3 (0.41) | ADORA2ADRD3KCNH2CACNA1GCACNA1H | |
| SCHEMBL14169941 | 0.74 | ALDH1A1 (0.41) | — | |
| SCHEMBL14169939 | 0.74 | OPRM1 (0.43) | ADORA2ADRD3KCNH2CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390801-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390801-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | THORSETT EUGENE D | 2007-08-30 | — | — | US | disclosed |
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | THORSETT EUGENE D | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | APP, BACE1, PSEN1 | FNTA 988/4885FNTB 1960/4885ACE 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.